Hepion director gets 299K stock options at $0.08

Hepion Pharmaceuticals, Inc. (HEPA) reported that director Michael J. Purcell received a grant of stock options on August 19, 2026 to acquire 299,000 shares of common stock at an exercise price of $0.08 per share.

Rhea-AI Filing Summary

Hepion Pharmaceuticals, Inc. (HEPA) reported that director Michael J. Purcell received a grant of stock options on August 19, 2026 to acquire 299,000 shares of common stock at an exercise price of $0.08 per share. These options become exercisable on August 19, 2027 and expire on August 19, 2036, leaving him with 299,000 options held directly after the award. No Rule 10b5-1 trading plan is reported for this grant.

Insider Trade Summary

Grant/Award: 299,000 shares

Grant/Award 1 txn

Insider Purcell Michael J.

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Options	299,000	$0.00	$0.00

Holdings After Transaction: Stock Options — 299,000 contracts (Direct)

Key Figures

Stock options granted: 299,000 options Exercise price: $0.08 per share Underlying common shares: 299,000 shares +3 more

6 metrics

Stock options granted 299,000 options Grant to director Michael J. Purcell on August 19, 2026

Exercise price $0.08 per share Exercise price for the 299,000 stock options

Underlying common shares 299,000 shares Shares of Hepion Pharmaceuticals common stock underlying the options

Post-grant option holdings 299,000 options Total stock options held directly by Michael J. Purcell after the grant

Option vesting date August 19, 2027 Date when the stock options become exercisable

Option expiration date August 19, 2036 Expiration date of the granted stock options

FAQ

What insider transaction did HEPA disclose for Michael J. Purcell?

Hepion Pharmaceuticals disclosed that director Michael J. Purcell received a grant of stock options on August 19, 2026 covering 299,000 shares of common stock. The options were awarded as a compensation-related acquisition rather than a market purchase.

How many HEPA shares are covered by the new stock options?

The new stock option award to Michael J. Purcell covers 299,000 shares of Hepion Pharmaceuticals common stock. After this grant, he directly holds 299,000 stock options according to the filing.

What is the exercise price of Michael J. Purcell’s HEPA stock options?

The stock options granted to Michael J. Purcell have an exercise price of $0.08 per share. This is the price at which he can purchase Hepion Pharmaceuticals common shares when the options become exercisable.

When do the newly granted HEPA stock options become exercisable and when do they expire?

The stock options granted to Michael J. Purcell become exercisable on August 19, 2027 and expire on August 19, 2036. After that expiration date, any unexercised options would no longer be usable.

Were Michael J. Purcell’s HEPA option grants made under a Rule 10b5-1 trading plan?

No. The filing indicates that no Rule 10b5-1 trading plan is reported for Michael J. Purcell’s August 19, 2026 stock option grant in Hepion Pharmaceuticals.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 09/10/2026 - 04:15 PM Accepted by SEC EDGAR 09/10/2026 - 04:15 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Purcell Michael J.

(Last) (First) (Middle)

C/O HEPION PHARMACEUTICALS, INC.

34 SHREWSBURY AVE., SUITE 1D

(Street)

RED BANK NEW JERSEY 07701

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Hepion Pharmaceuticals, Inc. [ HEPA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/19/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Options	$0.08	08/19/2026		A		299,000		08/19/2027	08/19/2036	Common Stock	299,000	$0	299,000	D

Explanation of Responses:

	/s/ Michael Purcell	09/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)